Class / Patent application number | Description | Number of patent applications / Date published |
514554000 | Amine addition salt of the acid | 33 |
20090042983 | Use of L-carnitine for the treatment of cardiovascular diseases - The use of L-carnitine or one of its pharmaceutically acceptable salts is described for the preparation of a medicine useful for reducing the number of deaths caused by acute myocardial infarction and for improving the short-and-long-term prognosis in the patients treated with it, in which L-carnitine is administered parenterally within the first few hours of onset of the symptoms of acute myocardial infarction at an initial dose of 9 grams a day for 5 days, after which the treatment is continued at a dose of 4 grams a day by the enteral route | 02-12-2009 |
20090270500 | 4-TRIMETHYLAMMONIO-BUTYRATES AS CPT2 INHIBITORS - This invention relates to novel 4-trimethylammoniobutyrates of the formula | 10-29-2009 |
20100173994 | Synthesis of triethylenetetramines - Methods and intermediates for synthesizing triethylenetetramine and salts thereof, as well as novel triethylenetetramine salts and their crystal structure, and triethylenetetramine salts of high purity. | 07-08-2010 |
20100204324 | Optically Active N-(Alpha-Mercaptopropionyl)Glycine - An optically active N-(α-mercaptopropionyl)glycine, i.e., R-(−)-N-(α-mercaptopropionyl)glycine or S-(−)-N-(α-mercaptopropionyl)glycine, a preparation method thereof, a pharmaceutical preparation containing the compound or a pharmaceutically acceptable salt or ester thereof, and use of the same in preparation of detoxification medicament for improving metabolism, are provided. | 08-12-2010 |
20100273879 | Method For Producing Acylglycinates - The invention relates to a method for producing acylglycinates of formula (I) | 10-28-2010 |
20110086916 | INTERVAL THERAPY FOR THE TREATMENT OF TINNITUS - The present invention relates to interval and/or maintenance therapy employing 1-amino-alkylcyclohexane derivatives (e.g., neramexane or a pharmaceutically acceptable salt thereof) for the treatment of an individual afflicted with tinnitus. | 04-14-2011 |
20110313040 | ORGANIC NUTRIENT SALTS, METHODS OF PREPARATION AND USES - The invention relates to organic nutrient salts, to compositions containing the same, to their preparation as well as their use. Preferred compositions include nutraceutical compositions and dietary supplements for use in neuroprotection and for improving or protecting cognitive and memory function. | 12-22-2011 |
20120010287 | N, N -DIMETHYL IMIDODICARBONIMIDIC DIAMIDE ACETATE, METHOD FOR PRODUCING THE SAME AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME - The present invention relates to N,N-dimethyl imidodicarbonimidic diamide acetate, a method of preparing the same and a pharmaceutical composition comprising the same, and more particularly, to N,N-dimethyl imidodicarbonimidic diamide acetate which is a crystalline acid addition salt prepared by reacting N,N-dimethyl imidodicarbonimidic diamide with acetic acid, and which is very effective as a therapeutic agent for treating metabolic syndromes that glycosuria and diabetes mellitus, obesity, hyperlipidemia, fatty liver, coronary heart disease, osteoporosis, polycystic ovarian syndrome, a cancer depleted of gene P53, etc. are complexly occurred; treating diabetes mellitus and preventing its complication; and treating a cancer and preventing myalgia, muscle cell cytotoxicity and rhabdomyolysis, etc. since the acid addition salt is excellent in physicochemical properties such as solubility, stability, non-hygroscopicity, anti-adhering property, etc., and low toxicity, a method of preparing the same and a pharmaceutical composition comprising the same. | 01-12-2012 |
20120059058 | DISPERSIONS OF RASAGILINE CITRATE - The subject invention provides a solid dispersion of rasagiline citrate, a composition and a process for the manufacture thereof. | 03-08-2012 |
20120065261 | Creatine compositions for skin treatment - The present invention relates to the use of creatine compounds, such as, for example, creatine monohydrate, creatine pyruvate and creatine ascorbate, for the treatment of skin. | 03-15-2012 |
20120178809 | Salt of Dimethylaminomethyl-Phenyl-Cyclohexane and Crystalline Forms Thereof - Novel 3-[2-(dimethylamino)methyl-(cyclohex-1-yl)]-phenol maleate compounds corresponding to formula I | 07-12-2012 |
20120184617 | PROCESS FOR PRODUCING FINGOLIMOD SALTS - The invention relates to a process for producing pharmaceutically acceptable salts of fingolimod (I), comprising the step of reacting N-[1,1-bis hydroxymethyl-3-(4-octyl phenyl)-propyl]-acylamide (II) with an acidic compound. Furthermore, the invention provides different pharmaceutically acceptable salts of fingolimod and a polymorphic form of fingolimod hydrochloride. | 07-19-2012 |
20120196933 | MEXILETINE PRODRUGS - The present invention concerns prodrugs of mexiletine (and mexiletine's active metabolite) pharmaceutical compositions containing such prodrugs. Methods for treating myotonic conditions, while reducing the inherent adverse GI side effects associated with mexiletine, increasing the bioavailability of mexiletine, and improving the pharmacokinetic reproducibility of mexiletine with the aforementioned prodrugs are also provided. | 08-02-2012 |
20130184347 | ACID ADDITION SALT OF A NORTRIPTYLINE-GABA CONJUGATE AND A PROCESS OF PREPARING SAME - An acid addition salt of a nortriptyline-GABA conjugate, a novel crystalline form of a fumaric acid addition salt of a nortriptyline-GABA conjugate, and processes of preparing the forgoing are disclosed. Uses of the above-indicated forms of a nortriptyline-GABA conjugate in the treatment of CNS disorders, and in the treatment of pain in particular, are also disclosed. Further disclosed in a large-scale process of preparing a nortriptyline-GABA conjugate. | 07-18-2013 |
20130296427 | NERAMEXANE FOR THE TREATMENT OR PREVENTION OF TINNITUS RELATED WITH STRESS OR ACUTE HEARING LOSS - Nerarnexane or a pharmaceutically acceptable salt thereof for use in the treatment or prevention of tinnitus, wherein said neramexane or a pharmaceutically acceptable salt thereof is administered to a patient afflicted with tinnitus caused by stress or acute hearing loss. | 11-07-2013 |
20140113965 | BRONCHODILATING BETA-AGONIST COMPOSITIONS AND METHODS - Bronchodilating compositions and methods are provided. The compositions are intended for administration as a nebulized aerosol. In certain embodiments, the compositions contain formoterol, or a derivative thereof. Methods for treatment, prevention, or amelioration of one or more symptoms of bronchoconstrictive disorders using the compositions provided herein are also provided. | 04-24-2014 |
20140194510 | DISPERSIONS OF RASAGILINE CITRATE - The subject invention provides a solid dispersion of rasagiline citrate, a composition and a process for the manufacture thereof. | 07-10-2014 |
20140249221 | Tri-Salt Form of Metformin - Provided herein are tri-salt compounds comprising a compound having two acidic functional groups and one basic functional groups (e.g., aspartate or glutamate), metformin, and polyunsaturated fatty acids, such as eicosapentaenoate or docosahexaenoate. The salts can be used in the treatment of diabetes, diabetes with concomitant dyslipidemia (e.g., high triglycerides) and diabetes exacerbated cardiovascular complications, such as cardiac arrhythmia, cardiac ischemia, myocardial infarction, cardiomyopathy, and stroke. The compounds of this invention are also useful in treating obesity. | 09-04-2014 |
20140323573 | METABOLIZABLE SALTS AND USE THEREOF IN DIAGNOSTICS AND THERAPY - The present invention proposes novel salt compounds for use in the diagnosis or therapy of a patient as well as drugs, medical products, diagnostic compositions or blood products containing a salt compound according to the invention. The salt compounds according to the invention comprise the cation of a metabolisable basic amino acid and the anion of a metabolisable carboxylic acid or an anion of carbonic acid. Those salt compounds therefore have the advantage that they are fully metabolisable and thus do not adversely affect the electrolyte balance or the acid-base balance of the patient. The proposed salt compounds are particularly suitable for the therapy of the liquid and electrolyte balance of a patient but also for adjusting the pH-value in a biological or medical sample, for adjusting the osmolality in infusion solutions, as buffer substances, for feeding biocarbonate to a patient and for inhibiting blood coagulation for example in a patient, in extracorporeal blood treatment in the diagnostic determination of blood coagulation or in the production, storage and preparation of blood products. | 10-30-2014 |
20140364500 | URSOLIC ACID SALTS FOR TREATING DIABETES AND OBESITY - The present invention relates to compounds having the following structure: | 12-11-2014 |
514555000 | Benzene ring in acid moiety | 13 |
20100292329 | 4-HYDROXY BENZOATE DERIVATIVES FOR USE IN THE TREATMENT OF INFECTION, INFLAMMATION OR PAIN - A compound of the general formula (I) is provided for use in the topical treatment of infection, inflammation and/or pain: wherein R | 11-18-2010 |
20110178174 | SALTS OF TRAMADOL AND IBUPROFEN AND THEIR CRYSTAL FORM IN THE TREATMENT OF PAIN - The present invention relates to salts and compositions of tramadol and ibuprofen, their crystal form, processes for preparation of the same and their uses for the treatment of pain. | 07-21-2011 |
20120101159 | IBUPROFEN LYSINATE ORAL SUSPENSION - The present invention refers to an ibuprofen lysinate-based pharmaceutical composition in the form of oral suspension and to the preparation procedure thereof. | 04-26-2012 |
20120157526 | TREATMENT OF PORTAL HYPERTENSION AND RESTORATION OF LIVER FUNCTION USING L-ORNITHINE PHENYLACETATE - Disclosed herein are methods of treating and/or preventing portal hypertension and/or restoring liver function using L-ornithine phenylacetate. | 06-21-2012 |
20120316238 | NOVEL POLYMOMORPH OF DESVENLAFAXINE BENZOATE - The present invention relates to a novel crystalline form L of (±)-desvenlafaxine benzoate and process for the preparing of the same. Further, the present invention also relates to pharmaceutical composition of novel crystalline form L of desvenlafaxine benzoate and one or more pharmaceutically acceptable excipient. | 12-13-2012 |
20130065957 | DICLOFENAC SALT OF TRAMADOL - The present invention relates to a compound of diclofenac-tramadol salt in 1:1 ratio and a pharmaceutical formulation comprising such compound. The present invention also relates to a method for treating a patient with moderate to moderately severe pain. The method comprises: identifying a patient suffering from moderate to moderately severe pain with pain intensity scale of 5-9, and administering to said patient the diclofenac-tramadol salt, in an effective amount. The method is particularly useful in treating postoperative pain after Cesarean, postoperative pain after non-Cesarean surgeries, cancer pain, osteoarthritis pain, or rheumatoid arthritis pain. | 03-14-2013 |
20130137769 | Injectable Preparations Of Diclofenac And Its Pharmaceutically Acceptable Salts - Injectable formulations of water-soluble salts of diclofenac, which cause significantly less pain at the site of injection and can be administered by intradeltoid route, in addition to intragluteal and slow intravenous route. | 05-30-2013 |
20130178529 | IBUPROFEN COMPOSITIONS AND METHODS OF MAKING SAME - The present invention provides an improved ibuprofen lysine pharmaceutical composition and a process for preparing the same. | 07-11-2013 |
20130289112 | SALTS OF KUKOAMINE B, PREPARATION METHOD AND USE THEREOF - Salts of kukoamine B, their preparation method and their pharmaceutical use in preparation of drugs for preventing and treating sepsis. Experiments indicate that salts of kukoamine B have a good effect on antagonizing the key factors inducing sepsis, and can be used in the preparation of drugs for preventing and treating sepsis. Under the current circumstances of the lack of effective measures for the treatment of sepsis in clinical practice, the medicinal formulations, which comprise the salts of kukoamine B, pharmaceutically acceptable carrier and/or diluent, provide a new approach for the prevention and treatment of sepsis. | 10-31-2013 |
20140128466 | COMPOUNDS FOR USE IN THE TREATMENT OF INFLAMMATORY BOWEL DISEASE - Described are compounds of the structural formula (I): Also provided are pharmacologically acceptable isomers and salts of the compound of (I). The compounds are useful in the treatment of inflammatory bowel disease. | 05-08-2014 |
20140303250 | Pharmaceutical Solid Compositions Containing Ibuprofen Salts - A pharmaceutical, non-effervescent, solid composition comprising a mixture of a pharmaceutically effective amount of a ibuprofen salt and a pharmaceutically acceptable strong base in a molar ratio of from 1:0.01 to 1:0.8, said composition being such that, when dissolved in drinkable water for dilution, imparts a pH value ranging from 9 to 9.5 to the obtained solution, which do not cause sensory irritation to the oral cavity especially to the back of the mouth and throat, when swallowed. | 10-09-2014 |
20160022820 | TRANSDERMAL DELIVERY SYSTEM - A transdermal delivery system comprising a composition comprising a physiologically active agent and a penetration enhancer wherein the penetration enhancer comprises a combination of (i) an ester of salicylic acid, preferably selected from the C | 01-28-2016 |
20160045470 | AMORPHOUS SOLID DISPERSION OF TREPROSTINIL DIETHANOLAMINE - The present application relates to the amorphous solid dispersion of treprostinil diethanolamine salt and the process for its preparation. | 02-18-2016 |